An innovative therapeutic educational program to support older drivers with cognitive disorders: Description of a randomized controlled trial study protocol

Older drivers face the prospect of having to adjust their driving habits because of health problems, which can include neurocognitive disorders. Self-awareness of driving difficulties and the interaction between individual with neurocognitive disorders and natural caregiver seem to be important levers for the implementation of adaptation strategies and for the subsequent voluntary cessation of driving when the cognitive disorders become too severe. This study aims to evaluate an educational program for patient/natural caregiver dyads who wish to implement self-regulation strategies in driving activity, and to improve self-awareness of driving ability. The ACCOMPAGNE program is based on seven group workshops, which target the dyad. The workshops deal with the impact of cognitive, sensory and iatrogenic disorders on driving. They tackle questions about responsibility, and about autonomy and social life. They also provide alternative solutions aimed at maintaining outward-looking activities even if driving is reduced or stopped. A randomized controlled trial is planned to evaluate the effectiveness of the program 2 months and 6 months after inclusion, and to compare this to the effectiveness of conventional approaches. The main outcome of this trial (i.e., the implementation of self-regulated driving strategies), will be measured based on scores on the “Current Self-Regulatory Practices” subscale of the Driver Perception and Practices Questionnaire. The Driving Habits Questionnaire will be used to measure secondary outcomes (indicators of driving changes; indicators of changes in mood, quality of life and caregiver burden; and self-awareness of driving abilities). Indicators will be collected for both patients and natural caregivers. This cognitive, social and psychological program should allow older individuals with cognitive disorders to drive more safely, and help to maintain the quality of life and mood of both patient and natural caregiver despite driving limitations. The patient's care path would be optimized, as he/she would become an actor in the process of giving up driving, which will, most certainly, be needed at some point in the progress of neurocognitive disorders. This process ranges from becoming aware of driving difficulties, to implementing self-regulation strategies, through to complete cessation of driving when necessary.Clinical trial registration numberNCT04493957

Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis

Atherosclerosis is an inflammatory vascular disease responsible for the first cause of mortality worldwide. Recent studies have clearly highlighted the critical role of the immunoinflammatory balance in the modulation of disease development and progression. However, the immunoregulatory pathways that control atherosclerosis remain largely unknown. We show that loss of suppressor of cytokine signaling (SOCS) 3 in T cells increases both interleukin (IL)-17 and IL-10 production, induces an antiinflammatory macrophage phenotype, and leads to unexpected IL-17–dependent reduction in lesion development and vascular inflammation. In vivo administration of IL-17 reduces endothelial vascular cell adhesion molecule–1 expression and vascular T cell infiltration, and significantly limits atherosclerotic lesion development. In contrast, overexpression of SOCS3 in T cells reduces IL-17 and accelerates atherosclerosis. We also show that in human lesions, increased levels of signal transducer and activator of transcription (STAT) 3 phosphorylation and IL-17 are associated with a stable plaque phenotype. These results identify novel SOCS3-controlled IL-17 regulatory pathways in atherosclerosis and may have important implications for the understanding of the increased susceptibility to vascular inflammation in patients with dominant-negative STAT3 mutations and defective Th17 cell differentiation

Quels freins et quels levier pour l'innovation sociale? Entretien avec Romain Debref et Mélissa Boudes

International audienceEntretien avec Romain Debref et Mélissa Boudes. Restitution du projet européen SIMPACT sur les fondements économiques des innovations sociales

Quels freins et quels leviers pour l’innovation sociale ?

National audienceEntretien avec Romain Debref et Mélissa Boudes. Restitution du projet européen SIMPACT sur les fondements économiques des innovations sociales

Rôle de la signalisation dépendante de STAT3 dans la modulation de l'inflammation et dans le développement de l'athérosclérose et l'anévrisme

PARIS7-Bibliothèque centrale (751132105) / SudocSudocFranceF

Quels freins et quels leviers pour l’innovation sociale ?

National audienceEntretien avec Romain Debref et Mélissa Boudes. Restitution du projet européen SIMPACT sur les fondements économiques des innovations sociales

Innovation sociale et enjeux de l’emploi en Europe ? Vers une appropriation des trajectoires dédiées à un développement soutenable ?

International audienc

Quels freins et quels leviers pour l’innovation sociale ?

International audienc

À propos du réemploi d’élément scénographiques : entretien avec Fleur Bernet et Mélissa Rouvinet

Entretien avec Fleur Bernet et Mélissa Rouvinet à l’occasion de leurs « écoscénographies » pour les mises en scène de la première partie de saison 2023-2024 du POCHE /GVE : “Solastalgie de Thomas Köck par Patric Bachmann et Olivier Keller, “Krach” de Philippe Malone par Guillaume Miramond et “Le Pays lointain” de Jean-Luc Lagarce par Mathieu Bertholet